SCA
PGNX

SAC Capital Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

SAC Capital Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-28,878
Closed -$118K – 1232
2014
Q1 		$118K Buy
+28,878
New +$148K ﹤0.01% 1656
2013
Q4 		– Sell
-32,206
Closed -$162K – 2061
2013
Q3 		$162K Buy
+32,206
New +$175K ﹤0.01% 1638

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SAC Capital Advisors's PGNX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2014, closing a stake of 28,878 shares — an estimated $118K sold.

SAC Capital Advisors first reported a position in PGNX in Q3 2013 and held it in 2 quarters. The position peaked at $162K in Q3 2013. 76 funds tracked by Wall St. Rank hold PGNX as of Q2 2014.

  • SAC Capital Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 28,878 Progenics Pharmaceuticals Inc shares in Q2 2014, an estimated $118K.
  • SAC Capital Advisors first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 2 quarters.
  • SAC Capital Advisors's Progenics Pharmaceuticals Inc position peaked at $162K in Q3 2013.
  • 76 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.